Gil Naor, founder and CEO, MitrAssist Medical Ltd., a company that is the developer of minimally invasive products for treating heart disease, announces that the company has received ISO 13485:2003 Certification for the design and development of implantable heart valve prostheses.
Today's standard treatment for mitral valve regurgitation (MR), blood leakage or backflow into the atrium, is open-heart surgery. MitrAssist's unique design preserves the ventricular dynamic mode of function and mechanism, known to be crucial for long-term patient outcome. MitrAssist's mitral valve prosthesis is delivered with a minimally invasive procedure via a small-diameter catheter, keeping the existing valve intact. With its unique design focused on natural mitral valve anatomy, the MitrAssist mitral valve prosthesis will enable faster transition to minimally invasive procedures for mitral repair.
"This is yet another small step for us moving forward towards developing a viable and effective solution to Mitral Valve Insufficiency, following our successful completion of the chronic animal study POC," Naor states
Latest from Today's Medical Developments
- Teleflex sells acute care and urology businesses for $2.03 billion
- HANNOVER MESSE: Where research and manufacturing meet
- What’s next for the design and manufacturing industry in 2026?
- Arcline to sell Medical Manufacturing Technologies to Perimeter Solutions
- Decline in German machine tool orders bottoming out
- Analysis, trends, and forecasts for the future of additive manufacturing
- BlueForge Alliance Webinar Series Part III: Integrate Nationally, Catalyze Locally
- Robot orders accelerate in Q3
